Lixte Biotechnology Holdings
East Setauket, US · Founded 2006 · Delaware corporation · 4 employees on LinkedIn
Lixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
Founders & leadership
Lixte Biotechnology Holdings was founded in 2006 by John Kovach.
JK
John KovachFounder
BV
Bas van der BaanCSO
GP
Geordan PursgloveCEO
PS
Peter StazzoneCFO
W(
Winson (Sze Chun) HoNamed on SEC filing
PP
Philip PalmedoNamed on SEC filing
Board
SF
Stephen FormanBoard director
YY
Yun YenBoard director
Reported raises · per SEC filings
Form D private placements$8M disclosed across 2 rounds · 2018–2023
▶$3.5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bas van der BaanDirector
- Yun YenDirector
- James MiserExecutive Officer
- Robert WeingartenExecutive Officer
- Regina BrownDirector
- John KovachExecutive Officer, Director
- Rene BernardsDirector
- Eric FormanExecutive Officer
- Stephen FormanDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Minimum investment
- $3.5M
- Sales commissions
- $210K
- Placement agents
- A.G.P. / ALLIANCE GLOBAL PARTNERS
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedDec 2018 · 15 investors · BiotechnologyRule 506(b)
▶$4.5MraisedDec 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen FormanDirector
- Yun YenDirector
- Winson (Sze Chun) HoDirector
- John KovachExecutive Officer, Director
- Philip PalmedoDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Minimum investment
- $50K
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapKite Pharma38 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Exelixis22 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Solu22 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Dialectic Therapeutics17 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies competing with Lixte Biotechnology Holdings for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lixte Biotechnology Holdings do?
- Lixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
- Who founded Lixte Biotechnology Holdings?
- Lixte Biotechnology Holdings was founded by John Kovach in 2006.
- How much funding has Lixte Biotechnology Holdings raised?
- Lixte Biotechnology Holdings has disclosed $8M raised across 2 rounds.
- Where is Lixte Biotechnology Holdings headquartered?
- Lixte Biotechnology Holdings is headquartered in East Setauket, US.